help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyazaki, Y.
Right arrow Articles by DeFronzo, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyazaki, Y.
Right arrow Articles by DeFronzo, R. A.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 9 4312-4319
Copyright © 2004 by The Endocrine Society

Effect of Pioglitazone on Circulating Adipocytokine Levels and Insulin Sensitivity in Type 2 Diabetic Patients

Yoshinori Miyazaki, Archana Mahankali, Estela Wajcberg, Mandeep Bajaj, Lawrence J. Mandarino and Ralph A. DeFronzo

University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas 78229-3900

Address all correspondence and requests for reprints to: Ralph A. DeFronzo, M.D., University of Texas Health Science Center, Diabetes Division, Room 3.380S, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900. E-mail: albarado{at}uthscsa.edu.

We examined the effect of pioglitazone (PIO) on circulating adipocytokine levels to elucidate the mechanisms by which thiazolidinediones improve insulin resistance in type 2 diabetes mellitus (T2DM). Twenty-three subjects with T2DM (age 54 ± 2 yr, body mass index 29 ± 1 kg/m2) were randomly assigned to receive placebo (n = 11) or PIO, 45 mg/d (n = 12), for 4 months. Before and after treatment, subjects received a 75-g oral glucose tolerance test (OGTT); euglycemic insulin clamp (40 mU/m2·min) with 3-3H-glucose; determination of fat mass (3H2O); and measurement of fasting glucose, free fatty acids (FFAs), leptin, adiponectin, and TNF{alpha} concentrations. After 4 months of PIO, fasting plasma glucose concentration ({Delta} = –2.7 mol/liter), mean plasma glucose during OGTT ({Delta} = –3.8 mol/liter), and hemoglobin A1c ({Delta} = 1.7%) decreased (P < 0.05 vs. placebo) without change in fasting or post-OGTT plasma insulin levels. Fasting FFAs ({Delta} = 168 µmol/liter) and TNF{alpha} ({Delta} = 0.7 pg/ml) concentrations decreased (P < 0.05 vs. placebo), whereas adiponectin ({Delta} = 8.7 µg/ml) increased (P < 0.01 vs. placebo). Despite the increase in body fat mass ({Delta} = 3.4 kg) after PIO, plasma leptin concentration did not change significantly. No changes in plasma glucose, FFAs, or adipocytokine levels were observed in placebo-treated subjects. During the insulin clamp, endogenous (hepatic) glucose production decreased ({Delta} = –2.67 µmol/fat-free mass·min, P < 0.05 vs. placebo), whereas metabolic clearance rate of glucose (MCR) increased ({Delta} = 0.58 ml/fat-free mass·min, P < 0.05 vs. placebo) after PIO. In all subjects, before and after PIO, the decrease in plasma FFA concentration was correlated with the changes in both endogenous (hepatic) glucose production (r = 0.47, P < 0.05) and MCR (r = –0.41, P < 0.05), whereas the increase in plasma adiponectin concentration was correlated with the change in endogenous (hepatic) glucose production (r = –0.70, P < 0.01) and MCR (r = 0.49, P < 0.05). These results suggest that the direct effects of PIO on adipose tissue to decrease plasma FFA levels and increase plasma adiponectin contribute to the improvements in hepatic and peripheral insulin sensitivity and glucose tolerance in patients with T2DM.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
H. Gotoh, T. Gohda, M. Tanimoto, Y. Gotoh, S. Horikoshi, and Y. Tomino
Contribution of subcutaneous fat accumulation to insulin resistance and atherosclerosis in haemodialysis patients
Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3474 - 3480.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. B. Koenen, C. J. Tack, J. M. Kroese, A. R. Hermus, F. C. G. Sweep, J. van der Laak, A. F. H. Stalenhoef, J. de Graaf, L. J. H. van Tits, and R. Stienstra
Pioglitazone Treatment Enlarges Subcutaneous Adipocytes in Insulin-Resistant Patients
J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4453 - 4457.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. Banga, R. Unal, P. Tripathi, I. Pokrovskaya, R. J. Owens, P. A. Kern, and G. Ranganathan
Adiponectin translation is increased by the PPAR{gamma} agonists pioglitazone and {omega}-3 fatty acids
Am J Physiol Endocrinol Metab, March 1, 2009; 296(3): E480 - E489.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
B. Ravikumar, J. Gerrard, C. Dalla Man, M. J. Firbank, A. Lane, P. T. English, C. Cobelli, and R. Taylor
Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content
Diabetes, September 1, 2008; 57(9): 2288 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Z. Szocs, B. Brunmair, K. Stadlbauer, P. Nowotny, L. Bauer, A. Luger, and C. Furnsinn
Age-Dependent Development of Metabolic Derangement and Effects of Intervention with Pioglitazone in Zucker Diabetic Fatty Rats
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 323 - 329.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Wajcberg, A. Sriwijitkamol, N. Musi, R. A. DeFronzo, and E. Cersosimo
Relationship between Vascular Reactivity and Lipids in Mexican-Americans with Type 2 Diabetes Treated with Pioglitazone
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1256 - 1262.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo
Thiazolidinediones improve beta-cell function in type 2 diabetic patients
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E871 - E883.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. M. Sharma and B. Staels
Peroxisome Proliferator-Activated Receptor {gamma} and Adipose Tissue--Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 386 - 395.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. J. Serlie, G. Allick, J. E. Groener, M. T. Ackermans, R. Heijligenberg, B. C. Voermans, J. M. Aerts, A. J. Meijer, and H. P. Sauerwein
Chronic Treatment with Pioglitazone Does Not Protect Obese Patients with Diabetes Mellitus Type II from Free Fatty Acid-Induced Insulin Resistance
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 166 - 171.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
T. Mazzone, P. M. Meyer, S. B. Feinstein, M. H. Davidson, G. T. Kondos, R. B. D'Agostino Sr, A. Perez, J.-C. Provost, and S. M. Haffner
Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial
JAMA, December 6, 2006; 296(21): 2572 - 2581.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. M. Bodles, A. Banga, N. Rasouli, F. Ono, P. A. Kern, and R. J. Owens
Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1100 - E1105.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. B. Watts and D. A. D'Alessio
Type 2 diabetes, thiazolidinediones: bad to the bone?
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3276 - 3278.
[Full Text] [PDF]

Home page
 DiabetesHome page
G. K. Bandyopadhyay, J. G. Yu, J. Ofrecio, and J. M. Olefsky
Increased Malonyl-CoA Levels in Muscle From Obese and Type 2 Diabetic Subjects Lead to Decreased Fatty Acid Oxidation and Increased Lipogenesis; Thiazolidinedione Treatment Reverses These Defects.
Diabetes, August 1, 2006; 55(8): 2277 - 2285.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
E. H. Leiter, P. C. Reifsnyder, W. Zhang, H.-j. Pan, Q. Xiao, and J. Mistry
Differential Endocrine Responses to Rosiglitazone Therapy in New Mouse Models of Type 2 Diabetes
Endocrinology, February 1, 2006; 147(2): 919 - 926.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Rasouli, A. Yao-Borengasser, L. M. Miles, S. C. Elbein, and P. A. Kern
Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression
Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E42 - E46.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Li, P. A. Hansen, L. Xi, R. A. S. Chandraratna, and C. F. Burant
Distinct Mechanisms of Glucose Lowering by Specific Agonists for Peroxisomal Proliferator Activated Receptor {gamma} and Retinoic Acid X Receptors
J. Biol. Chem., November 18, 2005; 280(46): 38317 - 38327.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
I. W Campbell
Pioglitazone -- an oral antidiabetic agent and metabolic syndrome modulator. Can theory translate into practice?
The British Journal of Diabetes & Vascular Disease, July 1, 2005; 5(4): 209 - 216.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
J.-M. Fernandez-Real, J. Vendrell, and W. Ricart
Circulating Adiponectin and Plasma Fatty Acid Profile
Clin. Chem., March 1, 2005; 51(3): 603 - 609.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society